• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

槲皮素:代谢功能障碍相关脂肪性肝病(MASLD)管理的有前途的候选药物。

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

机构信息

Science Circle of the Department of Inorganic Chemistry, Medical University of Lublin, Dr. Witolda Chodźki 4a, 20-093 Lublin, Poland.

Department of Inorganic Chemistry, Medical University of Lublin, Dr. Witolda Chodźki 4a, 20-093 Lublin, Poland.

出版信息

Molecules. 2024 Nov 6;29(22):5245. doi: 10.3390/molecules29225245.

DOI:10.3390/molecules29225245
PMID:39598636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11596905/
Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a chronic liver disease. The development of MASLD is influenced by a multitude of diseases associated with modern lifestyles, including but not limited to diabetes mellitus, hypertension, hyperlipidaemia and obesity. These conditions are often consequences of the adoption of unhealthy habits, namely a sedentary lifestyle, a lack of physical activity, poor dietary choices and excessive alcohol consumption. The treatment of MASLD is primarily based on modifying the patient's lifestyle and pharmacological intervention. Despite the absence of FDA-approved pharmacological agents for the treatment of MASLD, several potential therapeutic modalities have demonstrated efficacy in reversing the histopathological features of the disease. Among the botanical ingredients belonging to the flavonoid group is quercetin (QE). QE has been demonstrated to possess a number of beneficial physiological effects, including anti-inflammatory, anticancer and antifungal properties. Additionally, it functions as a natural antioxidant. Preclinical evidence indicates that QE may play a beneficial role in reducing liver damage and improving metabolic health. Early human studies also suggest that QE may be an effective treatment for MASLD due to its antioxidant, anti-inflammatory, and lipid-regulating properties. This review aims to summarize the available information on the therapeutic effects of QE in MASLD.

摘要

代谢相关脂肪性肝病(MASLD)是一种慢性肝病。MASLD 的发展受到多种与现代生活方式相关疾病的影响,包括但不限于糖尿病、高血压、高脂血症和肥胖症。这些疾病通常是不健康习惯的结果,例如久坐不动的生活方式、缺乏体育活动、不良的饮食选择和过量饮酒。MASLD 的治疗主要基于改变患者的生活方式和药物干预。尽管目前还没有获得 FDA 批准用于治疗 MASLD 的药物,但已有几种潜在的治疗方法已被证明可有效逆转该疾病的组织病理学特征。属于黄酮类的植物成分之一是槲皮素(QE)。QE 具有许多有益的生理作用,包括抗炎、抗癌和抗真菌特性。此外,它还具有天然抗氧化剂的功能。临床前证据表明,QE 可能通过减轻肝损伤和改善代谢健康发挥有益作用。早期人体研究也表明,由于 QE 具有抗氧化、抗炎和调节脂质的特性,因此可能是治疗 MASLD 的有效方法。本文旨在总结 QE 在 MASLD 中的治疗作用的现有信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/72be6418f746/molecules-29-05245-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/edc303928538/molecules-29-05245-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/24932ceafc1f/molecules-29-05245-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/3eb67ff9ddb1/molecules-29-05245-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/72be6418f746/molecules-29-05245-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/edc303928538/molecules-29-05245-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/24932ceafc1f/molecules-29-05245-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/3eb67ff9ddb1/molecules-29-05245-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dca/11596905/72be6418f746/molecules-29-05245-g004.jpg

相似文献

1
Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).槲皮素:代谢功能障碍相关脂肪性肝病(MASLD)管理的有前途的候选药物。
Molecules. 2024 Nov 6;29(22):5245. doi: 10.3390/molecules29225245.
2
Quercetin's Potential in MASLD: Investigating the Role of Autophagy and Key Molecular Pathways in Liver Steatosis and Inflammation.槲皮素在 MASLD 中的作用:研究自噬和关键分子通路在肝脂肪变性和炎症中的作用。
Nutrients. 2024 Nov 5;16(22):3789. doi: 10.3390/nu16223789.
3
Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options.代谢功能障碍相关脂肪性肝病及相关疾病的药物治疗:当前及新兴治疗选择
Pharmacol Rev. 2025 Mar;77(2):100018. doi: 10.1016/j.pharmr.2024.100018. Epub 2024 Nov 22.
4
Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.植物源疗法治疗代谢功能障碍相关脂肪性肝病。
Int J Mol Sci. 2024 May 21;25(11):5571. doi: 10.3390/ijms25115571.
5
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?白藜芦醇是否能改善代谢相关脂肪性肝病(MASLD)?
Int J Mol Sci. 2024 Mar 27;25(7):3746. doi: 10.3390/ijms25073746.
6
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment.连接心血管疾病与代谢功能障碍相关脂肪性肝病(MASLD):心脏代谢药物在MASLD治疗中的作用
Biomolecules. 2025 Feb 23;15(3):324. doi: 10.3390/biom15030324.
7
Inappropriate Diet Exacerbates Metabolic Dysfunction-Associated Steatotic Liver Disease via Abdominal Obesity.不当饮食通过腹部肥胖加剧代谢功能障碍相关脂肪性肝病。
Nutrients. 2024 Dec 5;16(23):4208. doi: 10.3390/nu16234208.
8
Therapeutic potential of the flavonoid compound Licochalcone D in metabolic dysfunction-associated steatotic liver disease.黄酮类化合物甘草查尔酮D在代谢功能障碍相关脂肪性肝病中的治疗潜力
Biochem Biophys Res Commun. 2025 Jan;744:151216. doi: 10.1016/j.bbrc.2024.151216. Epub 2024 Dec 20.
9
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎中心血管风险的降低
Curr Cardiol Rep. 2025 Jan 18;27(1):28. doi: 10.1007/s11886-024-02185-5.
10
The Impact of Dietary Interventions on Metabolic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Comorbid Conditions, Including Obesity and Type 2 Diabetes.饮食干预对代谢功能障碍相关脂肪性肝病(MASLD)及合并症(包括肥胖和2型糖尿病)代谢结局的影响
Nutrients. 2025 Apr 3;17(7):1257. doi: 10.3390/nu17071257.

引用本文的文献

1
Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver.预防代谢相关脂肪性肝病的饮食策略:针对脂肪肝的饮食模式综合综述
Metabolites. 2025 Aug 4;15(8):528. doi: 10.3390/metabo15080528.
2
Dietary quercetin intake is not associated with risk of metabolic dysfunction-associated steatotic liver disease in a general adult population.在普通成年人群中,膳食槲皮素摄入量与代谢功能障碍相关脂肪性肝病的风险无关。
Eur J Nutr. 2025 Jul 22;64(5):246. doi: 10.1007/s00394-025-03764-0.
3
Food plants as adjuvant medicines: a review of protective effects and clinical potential in alcoholic liver disease.

本文引用的文献

1
Natural bioactive compounds-The promising candidates for the treatment of intestinal failure-associated liver disease.天然生物活性化合物-治疗肠衰竭相关肝病的有前途的候选药物。
Clin Nutr. 2024 Sep;43(9):1952-1971. doi: 10.1016/j.clnu.2024.07.004. Epub 2024 Jul 14.
2
Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials-A Narrative Review.绿原酸在代谢功能障碍相关脂肪性肝病(MASLD)管理中的潜力:动物研究与临床试验——一项叙述性综述
Metabolites. 2024 Jun 20;14(6):346. doi: 10.3390/metabo14060346.
3
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
作为辅助药物的食用植物:对酒精性肝病保护作用及临床潜力的综述
Front Pharmacol. 2025 May 22;16:1586238. doi: 10.3389/fphar.2025.1586238. eCollection 2025.
4
Genome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis.肝脏的全基因组增强子-基因调控图谱揭示了非酒精性脂肪性肝病发病机制背后的新调控机制。
BMC Genomics. 2025 May 15;26(1):493. doi: 10.1186/s12864-025-11668-w.
5
Hepatoprotective Effect of Kaempferol-A Review.山奈酚的保肝作用——综述
Molecules. 2025 Apr 25;30(9):1913. doi: 10.3390/molecules30091913.
6
Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.用于递送抗肥胖天然化合物的脂质基纳米载体:靶向递送与精准治疗的进展
J Nanobiotechnology. 2025 May 7;23(1):336. doi: 10.1186/s12951-025-03412-z.
7
The mechanism study of quercetin isolated from maxim. inhibiting ferroptosis and alleviating MAFLD through p38 MAPK/ERK signaling pathway based on lipidomics and transcriptomics.基于脂质组学和转录组学对从 maxim. 中分离出的槲皮素通过 p38 MAPK/ERK 信号通路抑制铁死亡和减轻非酒精性脂肪性肝病的机制研究。
Front Pharmacol. 2025 Mar 31;16:1517291. doi: 10.3389/fphar.2025.1517291. eCollection 2025.
8
Chitosan-Folic Acid-Coated Quercetin-Loaded PLGA Nanoparticles for Hepatic Carcinoma Treatment.用于肝癌治疗的壳聚糖-叶酸包被的载槲皮素聚乳酸-羟基乙酸共聚物纳米粒
Polymers (Basel). 2025 Mar 31;17(7):955. doi: 10.3390/polym17070955.
白藜芦醇是否能改善代谢相关脂肪性肝病(MASLD)?
Int J Mol Sci. 2024 Mar 27;25(7):3746. doi: 10.3390/ijms25073746.
4
Recent advances in age-related metabolic dysfunction-associated steatotic liver disease.年龄相关性代谢功能障碍相关脂肪性肝病的最新进展。
World J Gastroenterol. 2024 Feb 21;30(7):652-662. doi: 10.3748/wjg.v30.i7.652.
5
Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets.非酒精性脂肪性肝病中的短链脂肪酸:短链脂肪酸作为治疗靶点的新前景
Heliyon. 2024 Feb 27;10(5):e26991. doi: 10.1016/j.heliyon.2024.e26991. eCollection 2024 Mar 15.
6
Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review.多酚类协同药物通过信号通路和肠道微生物群改善非酒精性脂肪性肝病:综述
J Adv Res. 2025 Feb;68:43-62. doi: 10.1016/j.jare.2024.03.004. Epub 2024 Mar 11.
7
The mitophagy pathway and its implications in human diseases.自噬途径及其在人类疾病中的意义。
Signal Transduct Target Ther. 2023 Aug 16;8(1):304. doi: 10.1038/s41392-023-01503-7.
8
Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease.天然化合物治疗非酒精性脂肪肝病的分子机制途径。
Molecules. 2023 Jul 25;28(15):5645. doi: 10.3390/molecules28155645.
9
ZNF143 inhibits hepatocyte mitophagy and promotes non-alcoholic fatty liver disease by targeting increased lncRNA NEAT1 expression to activate ROCK2 pathway.ZNF143 通过靶向增加的 lncRNA NEAT1 表达来激活 ROCK2 通路,抑制肝细胞自噬,促进非酒精性脂肪性肝病。
Epigenetics. 2023 Dec;18(1):2239592. doi: 10.1080/15592294.2023.2239592.
10
Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies.用于治疗代谢疾病的植物化学物质:来自临床研究的证据。
Biomed Pharmacother. 2023 Sep;165:115274. doi: 10.1016/j.biopha.2023.115274. Epub 2023 Aug 3.